I was pretty impressed by this trial. Peanut allergy is a serious problem in the US (and abroad). The goal of the treatment isn't to cure people of peanut allergy, but to make it so that accidental exposure isn't life-threatening.
In this trial, ~70% of patients who received the active drug were able to tolerate the peanut equivalent of a bite of a peanut butter sandwich without serious consequences, compared to 0% of patients receiving the placebo.
Particularly exciting, in a subsequent trial, patients from the placebo arm who crossed-over to the active drug achieved similar results (helping to suggest the result wasn't an effect of imbalance in study arms).
The company, Aimmune (AIMT), is expected to post results from their phase 3 trial any day now.